for intravenous use Initial U.S. Approval: 2013
Facts about obinutuzumab injection
Approval Date: 2013
Proprietary Name: On Request
Active Ingredient(s): obinutuzumab
Dosage Forms And Strengths: 1000 mg/40 mL (25 mg/mL) single-dose vial.
Current indications: chronic lymphocytic leukemia; follicular lymphoma
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “obinutuzumab injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For obinutuzumab injection
Approved accessible "obinutuzumab injection"
Obinutuzumab is prescribed to treat chronic lymphocytic leukemia (CLL) in combination with chlorambucil in adult patients who have not been previously treated for CLL. Obinutuzumab in combination with bendamustine is used to treat follicular lymphoma (FL) followed by obinutuzumab monotherapy in patients whose cancer condition has returned or not responded to other cancer treating medications.
FDA approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).
On 19 June 2015, orphan designation (EU/3/15/1504) was granted by the European Commission to Roche Registration Limited, United Kingdom, for obinutuzumab for the treatment of follicular lymphoma. Obinutuzumab for treatment of follicular lymphoma has been authorised in the EU as Gazyvaro since 13 June 2016.
How can 1 go about obtaining obinutuzumab injection?
If obinutuzumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
GAZYVA (obinutuzumab) injection, for intravenous use Initial U.S. Approval: 2013
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398